This site is intended for US healthcare professionals only.

BETHKIS LOGO

Email a colleague

Home/Savings & Support

Chiesi CareDirect LOGO

Savings and support for your patients

Give your CF patients the support they need with Chiesi CareDirect®

 

Patients can Start, Stay, and Save on BETHKIS

 

Chiesi CareDirect is a comprehensive support program designed to help patients start, stay, and save on BETHKIS® (Tobramycin Inhalation Solution). Enroll patients in Chiesi CareDirect to help them take advantage of these valuable resources. Patients who use government-funded plans (Medicaid, Medicare Part D, etc) are not eligible for Chiesi CareDirect. See terms and conditions +.

 

Terms and Conditions:

BETHKIS Copay Assistance Program: is available to patients with commercial insurance. Patients pay $0 out-of-pocket costs toward their BETHKIS prescription up to a monthly maximum of $1440. To obtain this benefit, patients must be enrolled in Chiesi CareDirect and utilize one of the network specialty pharmacies. Upon enrollment, the offer is valid for 12 months of copay assistance. Patients with primary enrollment in government-funded plans are not eligible for copay assistance.

 

BETHKIS Nutrition Debit Card: Patients must call 1-888-865-1222 to sign up for the $50 BETHKIS Nutrition Debit Card. For every qualifying monthly prescription of BETHKIS that Patient fills, they can receive $50 for their choice of vitamin supplements, high-calorie drinks or other nutritional food sources. This offer covers up to $300 for an entire year supply of BETHKIS. Patients receiving Medicare, Medicaid, or that are participating in any other state or federally subsidized pharmacy benefit program are not eligible for the Nutrition Debit Card Program. Chiesi USA reserves the right to rescind, revoke, or amend this offer without notice at any time. This offer is good only in the U.S. The Card and Program expire on 12/31/16. Patients participating in Chiesi USA’s Patient Assistance Program are not eligible.

 

PAP eligibility requirements:

  • Legal US resident
  • Income level within specified guidelines
  • Uninsured or underinsured:
    • Commercially insured patients without prescription coverage are eligible
    • Commercially insured patients with no plan coverage for product are eligible
    • Commercially insured patients appealing plan determination are eligible (during the appeal process)
  • Patients with a Government Funded plan are not eligible for PAP (Medicare Part D, Medicaid, etc.)
  • Commercially insured patients with high out-of-pocket costs are not considered eligible. Product is considered covered

 

$0 icon

Eligible patients can pay as little as $0 per month*

  • Patients pay as little as $0 for their copay and deductible
Phone icon

Personal Patient Navigator

  • Each patient is assigned to a dedicated Patient Navigator for 1-on-1 support at the start of their therapy
    • The Patient Navigator calls patients to check on their treatment and coverage
    • Adherence reports on each patient are sent to HCPs so they can better monitor treatment
$50 icon

Up to $50 per month Nutrition Debit Card

  • Patient nutrition needs and food preferences can change over time. This debit card helps patients buy the food and nutritional supplements of their choice
    • Up to $50 per month is loaded onto the card every time patients fill their BETHKIS prescription
Free Kits icon

Free nebulizer kits and aerosol delivery systems

  • Patients can receive free PARI LC PLUS® nebulizer kits and Aerosol Delivery Systems
Hands icon

Patient Assistance Program

  • Available for qualified patients who are unisured or underinsured and cannot afford their medication
Clock icon

Fast benefits investigation & reimbursement support

  • Specialists assist with benefits investigations, prior authorizations (PA), claims, appeals, and referrals
  • Most benefits investigations are completed within 24 hours
Checklist icon

Support with CoverMyMeds®

  • CoverMyMeds automates the PA process online with easy-to-use forms, information, and assistance

 

 

Two simple options to get started

  1. Complete and send a Service Request Form via fax or email

Download form

  1. Complete a Service Request Form electronically at CoverMyMeds.com

 

Capture patient authorization signatures electronically with eHIPAA.com

If patients are not able to sign forms in the office, patients can provide their signature from home through fax, scan, or email using eHIPAA.com.

 


For more information

Contact a Chiesi CareDirect Specialist toll-free at 1-888-865-1222 from 9 am to 6 pm ET, Monday through Friday. You can also email chiesicaredirect@caremetx.com.
*Restrictions apply.
†Limit one card per person per month. Patients receiving Medicare, Medicaid, or that are participating in any other state federally subsidized pharmacy benefit program are not eligible for the Nutrition Debit Card Program.

 

Indication

BETHKIS® (Tobramycin Inhalation Solution) is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.

Important Safety Information

BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside.

Bronchospasm can occur with inhalation of BETHKIS. Bronchospasm and wheezing should be treated as medically appropriate.

Caution should be exercised when prescribing BETHKIS to patients with known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. Audiograms, serum concentration, and renal function should be monitored as appropriate.

Avoid concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential.

BETHKIS should not be administered concurrently with ethacrynic acid, furosemide, urea, or mannitol.

Aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.

Fetal harm can occur when aminoglycosides are administered to a pregnant woman. Apprise women of the potential hazard to the fetus.

Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


Please see full prescribing information.


This website is intended for United States residents only.


Terms and Conditions:

BETHKIS Copay Assistance Program: is available to patients with commercial insurance. Patients pay $0 out-of-pocket costs toward their BETHKIS prescription up to a monthly maximum of $1440. To obtain this benefit, patients must be enrolled in Chiesi CareDirect and utilize one of the network specialty pharmacies. Upon enrollment, the offer is valid for 12 months of copay assistance. Patients with primary enrollment in government-funded plans are not eligible for copay assistance.

BETHKIS Nutrition Debit Card: Patients must call 1-888-865-1222 to sign up for the $50 BETHKIS Nutrition Debit Card. For every qualifying monthly prescription of BETHKIS that Patient fills, they can receive $50 for their choice of vitamin supplements, high-calorie drinks or other nutritional food sources. This offer covers up to $300 for an entire year supply of BETHKIS. Patients receiving Medicare, Medicaid, or that are participating in any other state or federally subsidized pharmacy benefit program are not eligible for the Nutrition Debit Card Program. Chiesi USA reserves the right to rescind, revoke, or amend this offer without notice at any time. This offer is good only in the U.S. The Card and Program expire on 12/31/16. Patients participating in Chiesi USA’s Patient Assistance Program are not eligible.

PAP eligibility requirements:

  • Legal US resident
  • Income level within specified guidelines
  • Uninsured or underinsured:
    • Commercially insured patients without prescription coverage are eligible
    • Commercially insured patients with no plan coverage for product are eligible
    • Commercially insured patients appealing plan determination are eligible (during the appeal process)
  • Patients with a Government Funded plan are not eligible for PAP (Medicare Part D, Medicaid, etc.)

  • Commercially insured patients with high out-of-pocket costs are not considered eligible. Product is considered covered

References: 1. BETHKIS [package insert]. Cary, NC: Chiesi USA, Inc.; 2014. 2. Chuchalin A, Csiszér E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr Drugs. 2007;9(suppl 1):21-31. 3. Poli G, Acerbi D, Pennini R, et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi®. Pediatr Drugs. 2007;9(suppl 1):3-9. 4. Data on file. Chiesi USA, Inc.

Are you a patient, caregiver, or healthcare professional?

I AM A PATIENT/CAREGIVER

- or -

I AM A HEALTHCARE PROFESSIONAL